A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Trial Profile

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Mirogabalin (Primary) ; Pregabalin
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 16 Nov 2016 Results analysing secondary efficacy endpoints including modified brief pain inventory (BPI) score and average daily sleep interference score (ADSIS) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 30 Sep 2016 Results of key secondary outcomes presented at the 16th World Congress on Pain
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top